List of Excipients in API EVEROLIMUS
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing EVEROLIMUS
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | ZORTRESS | everolimus | 0078-0417 | ANHYDROUS LACTOSE | |
| Novartis Pharmaceuticals Corporation | ZORTRESS | everolimus | 0078-0417 | BUTYLATED HYDROXYTOLUENE | |
| Novartis Pharmaceuticals Corporation | ZORTRESS | everolimus | 0078-0417 | CROSPOVIDONE | |
| Novartis Pharmaceuticals Corporation | ZORTRESS | everolimus | 0078-0417 | HYPROMELLOSES | |
| Novartis Pharmaceuticals Corporation | ZORTRESS | everolimus | 0078-0417 | LACTOSE MONOHYDRATE | |
| Novartis Pharmaceuticals Corporation | ZORTRESS | everolimus | 0078-0417 | MAGNESIUM STEARATE | |
| Novartis Pharmaceuticals Corporation | AFINITOR | everolimus | 0078-0566 | ANHYDROUS LACTOSE | |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Excipients in ANDA-approved (generic) drugs containing EVEROLIMUS
Detailed excipient profiles for EVEROLIMUS
Excipient focus: ACETONE
EVEROLIMUS drug variants containing ACETONE
| Company | Ingredient | NDC |
|---|---|---|
| Breckenridge Pharmaceutical Inc | everolimus | 51991-821 |
| Natco Pharma Limited | everolimus | 63850-0058 |
| >Company | >Ingredient | >NDC |
EVEROLIMUS drug variants not containing ACETONE
Excipient focus: ANHYDROUS LACTOSE
EVEROLIMUS drug variants containing ANHYDROUS LACTOSE
EVEROLIMUS drug variants not containing ANHYDROUS LACTOSE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: BUTYLATED HYDROXYTOLUENE
EVEROLIMUS drug variants containing BUTYLATED HYDROXYTOLUENE
EVEROLIMUS drug variants not containing BUTYLATED HYDROXYTOLUENE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CROSCARMELLOSE SODIUM
EVEROLIMUS drug variants containing CROSCARMELLOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| Mylan Pharmaceuticals Inc | everolimus | 0378-0005 |
| Mylan Pharmaceuticals Inc | everolimus | 0378-3096 |
| >Company | >Ingredient | >NDC |
EVEROLIMUS drug variants not containing CROSCARMELLOSE SODIUM
Excipient focus: CROSPOVIDONE
EVEROLIMUS drug variants containing CROSPOVIDONE
EVEROLIMUS drug variants not containing CROSPOVIDONE
| Company | Ingredient | NDC |
|---|---|---|
| Mylan Pharmaceuticals Inc | everolimus | 0378-3096 |
| >Company | >Ingredient | >NDC |
Excipient focus: HYPROMELLOSE
EVEROLIMUS drug variants containing HYPROMELLOSE
| Company | Ingredient | NDC |
|---|---|---|
| Breckenridge Pharmaceutical Inc | everolimus tablets | 51991-379 |
| >Company | >Ingredient | >NDC |
EVEROLIMUS drug variants not containing HYPROMELLOSE
Excipient focus: HYPROMELLOSE 2208
EVEROLIMUS drug variants containing HYPROMELLOSE 2208
| Company | Ingredient | NDC |
|---|---|---|
| Upsher-Smith Laboratories LLC | everolimus | 0245-0822 |
| Biocon Pharma Inc | everolimus | 70377-010 |
| NorthStar RxLLC | everolimus | 72603-254 |
| >Company | >Ingredient | >NDC |
EVEROLIMUS drug variants not containing HYPROMELLOSE 2208
Excipient focus: HYPROMELLOSE 2910
EVEROLIMUS drug variants containing HYPROMELLOSE 2910
EVEROLIMUS drug variants not containing HYPROMELLOSE 2910
Excipient focus: HYPROMELLOSES
EVEROLIMUS drug variants containing HYPROMELLOSES
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | everolimus | 0078-0417 |
| Novartis Pharmaceuticals Corporation | everolimus | 0078-0566 |
| Natco Pharma Limited | everolimus | 63850-0062 |
| Ascend Laboratories LLC | everolimus | 67877-718 |
| >Company | >Ingredient | >NDC |
EVEROLIMUS drug variants not containing HYPROMELLOSES
Excipient focus: LACTOSE MONOHYDRATE
EVEROLIMUS drug variants containing LACTOSE MONOHYDRATE
EVEROLIMUS drug variants not containing LACTOSE MONOHYDRATE
Excipient focus: MAGNESIUM STEARATE
EVEROLIMUS drug variants containing MAGNESIUM STEARATE
EVEROLIMUS drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MANNITOL
EVEROLIMUS drug variants containing MANNITOL
| Company | Ingredient | NDC |
|---|---|---|
| Mylan Pharmaceuticals Inc | everolimus | 0378-0005 |
| >Company | >Ingredient | >NDC |
EVEROLIMUS drug variants not containing MANNITOL
Excipient focus: MICROCRYSTALLINE CELLULOSE 102
EVEROLIMUS drug variants containing MICROCRYSTALLINE CELLULOSE 102
| Company | Ingredient | NDC |
|---|---|---|
| Mylan Pharmaceuticals Inc | everolimus | 0378-0005 |
| >Company | >Ingredient | >NDC |
EVEROLIMUS drug variants not containing MICROCRYSTALLINE CELLULOSE 102
Excipient focus: SILICON DIOXIDE
EVEROLIMUS drug variants containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Mylan Pharmaceuticals Inc | everolimus | 0378-0005 |
| Mylan Pharmaceuticals Inc | everolimus | 0378-3096 |
| Par Pharmaceutical Inc | everolimus | 49884-119 |
| >Company | >Ingredient | >NDC |
EVEROLIMUS drug variants not containing SILICON DIOXIDE
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
© Copyright 2002-2024 thinkBiotech LLC
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Preferred Citation:
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Links
Follow DrugPatentWatch:
